136 related articles for article (PubMed ID: 35840514)
1. Vinorelbine After Prior Treatment With Eribulin for Advanced Breast Cancer: A Single-Centre Experience Suggesting Cross-Resistance.
Okines AFC; Irfan T; Mohammed K; Ring A; Parton M; Kipps E; Johnston S; Turner NC
Clin Breast Cancer; 2022 Oct; 22(7):e825-e831. PubMed ID: 35840514
[TBL] [Abstract][Full Text] [Related]
2. A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting.
Dranitsaris G; Beegle N; Kalberer T; Blau S; Cox D; Faria C
J Oncol Pharm Pract; 2015 Jun; 21(3):170-7. PubMed ID: 24620009
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness analysis of monotherapy with cytotoxic agents in triple-negative metastatic breast cancer in a community setting.
Dranitsaris G; Gluck S; Faria C; Cox D; Rugo H
Clin Ther; 2015 Jan; 37(1):134-44. PubMed ID: 25433768
[TBL] [Abstract][Full Text] [Related]
4. Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.
Aftimos P; Polastro L; Ameye L; Jungels C; Vakili J; Paesmans M; van den Eerenbeemt J; Buttice A; Gombos A; de Valeriola D; Gil T; Piccart-Gebhart M; Awada A
Eur J Cancer; 2016 Jun; 60():117-24. PubMed ID: 27107326
[TBL] [Abstract][Full Text] [Related]
5. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial.
Yuan P; Hu X; Sun T; Li W; Zhang Q; Cui S; Cheng Y; Ouyang Q; Wang X; Chen Z; Hiraiwa M; Saito K; Funasaka S; Xu B
Eur J Cancer; 2019 May; 112():57-65. PubMed ID: 30928806
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
McIntyre K; O'Shaughnessy J; Schwartzberg L; Glück S; Berrak E; Song JX; Cox D; Vahdat LT
Breast Cancer Res Treat; 2014 Jul; 146(2):321-8. PubMed ID: 24699910
[TBL] [Abstract][Full Text] [Related]
7. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.
Ortega V; Antón A; Garau I; Afonso N; Calvo L; Fernández Y; Martínez-García M; Blanco E; Zamora P; García M; Illarramendi JJ; Rodríguez Sánchez CA; Sampayo M; Aguirre E; Pérez-García JM; Cortés J; Llombart-Cussac A
Clin Breast Cancer; 2019 Apr; 19(2):105-112. PubMed ID: 30679100
[TBL] [Abstract][Full Text] [Related]
8. A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer.
Katakami N; Felip E; Spigel DR; Kim JH; Olivo M; Guo M; Nokihara H; Yang JC; Iannotti N; Satouchi M; Barlesi F
Ann Oncol; 2017 Sep; 28(9):2241-2247. PubMed ID: 28911085
[TBL] [Abstract][Full Text] [Related]
9. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy.
Pivot X; Marmé F; Koenigsberg R; Guo M; Berrak E; Wolfer A
Ann Oncol; 2016 Aug; 27(8):1525-31. PubMed ID: 27177860
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
Ates O; Babacan T; Kertmen N; Sarici F; Cenoli A; Akin S; Karakas Y; Kilickap S; Ozisik Y; Sever AR; Aksoy S; Altundag K
J BUON; 2016; 21(2):375-81. PubMed ID: 27273947
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.
Twelves C; Cortes J; Vahdat L; Olivo M; He Y; Kaufman PA; Awada A
Breast Cancer Res Treat; 2014 Dec; 148(3):553-61. PubMed ID: 25381136
[TBL] [Abstract][Full Text] [Related]
12. A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden.
Kessler L; Falato C; Margolin S; Bergh J; Foukakis T
Acta Oncol; 2015 Apr; 54(4):522-9. PubMed ID: 25383448
[TBL] [Abstract][Full Text] [Related]
13. Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
Aogi K; Watanabe K; Kitada M; Sangai T; Ohtani S; Aruga T; Kawaguchi H; Fujisawa T; Maeda S; Morimoto T; Sato N; Takao S; Morita S; Masuda N; Toi M; Ohno S
Int J Clin Oncol; 2021 Jul; 26(7):1229-1236. PubMed ID: 33891194
[TBL] [Abstract][Full Text] [Related]
14. Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE.
Leo S; Arnoldi E; Repetto L; Coccorullo Z; Cinieri S; Fedele P; Cazzaniga M; Lorusso V; Latorre A; Campanella G; Ciccarese M; Accettura C; Pisconti S; Rinaldi A; Brunetti C; Raffaele M; Coltelli L; Spazzapan S; Fratino L; Petrucelli L; Biganzoli L
Oncologist; 2019 Jun; 24(6):e232-e240. PubMed ID: 30413667
[TBL] [Abstract][Full Text] [Related]
15. Incidence of peripheral neuropathy associated with eribulin mesylate versus vinorelbine in patients with metastatic breast cancer: sub-group analysis of a randomized phase III study.
Wu Y; Wang Q; Zhang J; Cao J; Wang B; Hu X
Support Care Cancer; 2020 Aug; 28(8):3819-3829. PubMed ID: 31832821
[TBL] [Abstract][Full Text] [Related]
16. Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study.
Nakamoto S; Watanabe J; Ohtani S; Morita S; Ikeda M
BMC Cancer; 2022 Jan; 22(1):31. PubMed ID: 34980019
[TBL] [Abstract][Full Text] [Related]
17. A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes.
Kimura K; Iwamoto M; Tanaka S; Yamamoto D; Yoshidome K; Ogura H; Terasawa R; Matsunami N; Takahashi Y; Nitta T; Morimoto T; Fujioka H; Kawaguchi K; Uchiyama K
Cancer Chemother Pharmacol; 2018 May; 81(5):923-933. PubMed ID: 29594360
[TBL] [Abstract][Full Text] [Related]
18. Eribulin mesylate for the treatment of late-stage breast cancer.
Gourmelon C; Frenel JS; Campone M
Expert Opin Pharmacother; 2011 Dec; 12(18):2883-90. PubMed ID: 22087618
[TBL] [Abstract][Full Text] [Related]
19. First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer.
Araki K; Fukada I; Yanagi H; Kobayashi K; Shibayama T; Horii R; Takahashi S; Akiyama F; Ohno S; Ito Y
Breast; 2017 Oct; 35():78-84. PubMed ID: 28662406
[TBL] [Abstract][Full Text] [Related]
20. Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a "physician's choice" control arm in a randomized approval trial.
Donoghue M; Lemery SJ; Yuan W; He K; Sridhara R; Shord S; Zhao H; Marathe A; Kotch L; Jee J; Wang Y; Zhou L; Adams WM; Jarral V; Pilaro A; Lostritto R; Gootenberg JE; Keegan P; Pazdur R
Clin Cancer Res; 2012 Mar; 18(6):1496-505. PubMed ID: 22282463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]